- AstraZeneca Plc AZN has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19.
- The application seeks approval for AZD7442 to prevent COVID-19 for people who respond poorly to vaccines because of a weakened immune system.
- Related: AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%.
- If approved, AZD7442 would be the first LAAB to receive a EUA for COVID-19 prevention.
- Talks regarding supply agreements for AZD7442 are ongoing with the United States and other governments.
- AZD7442 was optimized using AstraZeneca's proprietary YTE half-life extension technology, which more than triples the durability of its action compared to conventional antibodies.
- Preliminary 'in vitro' findings of AZD7442 demonstrated broad anti-COVID activity, particularly neutralized viral variants, including the Delta and Mu variants.
- Related Link: Merck COVID-19 Oral Antiviral Cuts Risk of Hospitalization, Death By 50%.
- Price Action: AZN stock is down 0.31% at $60.35 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in